Patents Assigned to ELORAC, INC.
  • Patent number: 11478439
    Abstract: Improved methods and compositions are disclosed for treating dry eye by administering intranasally a therapeutically effective amount of a capsaicinoid compound embedded in multiple layers of solid lamellar crystals of monoglycerides to patients with deficient tear production. The lipophilic capsaicinoid drug is embedded in multiple layers of solid lamellar crystals of monoglycerides, and these crystals are incorporated into pharmaceutically acceptable vehicles comprised of solutions, suspensions, foams, creams, ointments, and gels. The resulting formulations of the capsaicinoid are suitable for application to the nasal mucosa or skin and are more stable, less irritating to skin and mucous membranes, and provide increased and more controlled release of the capsaicinoid compound.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: October 25, 2022
    Assignee: Elorac, Inc.
    Inventor: Joel E. Bernstein
  • Patent number: 11166925
    Abstract: Improved methods and compositions are disclosed for treating dry eye by administering intranasally a therapeutically effective amount of a capsaicinoid compound embedded in multiple layers of solid lamellar crystals of monoglycerides to patients with deficient tear production. The lipophilic capsaicinoid drug is embedded in multiple layers of solid lamellar crystals of monoglycerides, and these crystals are incorporated into pharmaceutically acceptable vehicles comprised of solutions, suspensions, foams, creams, ointments, and gels. The resulting formulations of the capsaicinoid are more stable, less irritating to skin and mucous membranes, and provide increased and more controlled release of the capsaicinoid compound.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: November 9, 2021
    Assignee: ELORAC, INC.
    Inventor: Joel E. Bernstein
  • Publication number: 20170143752
    Abstract: A method and composition for treating chronic inflammatory disorders comprising a pharmaceutically acceptable carrier suitable for oral administration or injection and containing a therapeutic amount of a complex of dietary supplement ingredients comprising nicotinamide, quercetin, curcumin, EPA, DHA, hesperetin and glychrrhizin.
    Type: Application
    Filed: October 30, 2016
    Publication date: May 25, 2017
    Applicant: ELORAC INC
    Inventor: JOEL E. BERNSTEIN
  • Patent number: 9545419
    Abstract: A method and composition for treating chronic inflammatory disorders comprising a pharmaceutically acceptable carrier suitable for oral administration or injection and containing a therapeutic amount of a complex of dietary supplement ingredients comprising nicotinamide, quercetin, curcumin, EPA, DHA, hesperetin and glychrrhizin.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: January 17, 2017
    Assignee: ELORAC INC
    Inventor: Joel E Bernstein
  • Patent number: 8604047
    Abstract: Methods and compositions are described for the treatment of very severe acne vulgaris, including nodulocystic acne and conglobate acne. Compounds which inhibit either or both type 1 and type 2 isoforms of steroid 5?-reductase are administered daily in either oral or topical formulations to patients suffering from severe forms of acne vulgaris. Very high dosages of such compounds can effectively be administered oral just once a week and be successful.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: December 10, 2013
    Assignee: Elorac, Inc.
    Inventor: Joel E. Bernstein
  • Publication number: 20110256237
    Abstract: Methods and compositions are described for treating acne vulgaris and acne rosacea by administering compositions suitable for oral administration. Suitable compositions contain high dosages of the vitamin nicotinamide combined with much lower dosages of azelaic acid.
    Type: Application
    Filed: April 16, 2010
    Publication date: October 20, 2011
    Applicant: ELORAC, INC.
    Inventor: Joel E. Bernstein